High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

AIMS: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion in natalizumab-treated patients. BACKGROUND: Natalizumab is highly effective for the treatment of relapsing–remitting multiple sclerosis (RRMS), but its use is complicated by opportunistic JCV infectio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ther Adv Neurol Disord
Hauptverfasser: Dwyer, Christopher M., Jokubaitis, Vilija G., Stankovich, Jim, Baker, Josephine, Haartsen, Jodi, Butzkueven, Helmut, Cartwright, Adriana, Shuey, Neil, Fragoso, Yara Dadalti, Rath, Louise, Skibina, Olga, Fryer, Kylie, Butler, Ernest, Coleman, Jennifer, MacIntrye, Jennifer, Macdonell, Richard, van der Walt, Anneke
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2021
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8053827/
https://ncbi.nlm.nih.gov/pubmed/33948117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286421998915
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge